| 000 | 01742 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517120205.0 | ||
| 264 | 0 | _c20170601 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1097-0142 | ||
| 024 | 7 |
_a10.1002/cncr.30325 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMesa, Ruben A | |
| 245 | 0 | 0 |
_aDifferences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. _h[electronic resource] |
| 260 |
_bCancer _c02 2017 |
||
| 300 |
_a449-458 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aOncologists |
| 650 | 0 | 4 | _aPatient Education as Topic |
| 650 | 0 | 4 | _aPatients |
| 650 | 0 | 4 |
_aPolycythemia Vera _xdrug therapy |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _xdrug therapy |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurveys and Questionnaires |
| 650 | 0 | 4 |
_aThrombocythemia, Essential _xdrug therapy |
| 650 | 0 | 4 |
_aThrombosis _xdrug therapy |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aMiller, Carole B | |
| 700 | 1 | _aThyne, Maureen | |
| 700 | 1 | _aMangan, James | |
| 700 | 1 | _aGoldberger, Sara | |
| 700 | 1 | _aFazal, Salman | |
| 700 | 1 | _aMa, Xiaomei | |
| 700 | 1 | _aWilson, Wendy | |
| 700 | 1 | _aParanagama, Dilan C | |
| 700 | 1 | _aDubinski, David G | |
| 700 | 1 | _aNaim, Ahmad | |
| 700 | 1 | _aParasuraman, Shreekant | |
| 700 | 1 | _aBoyle, John | |
| 700 | 1 | _aMascarenhas, John O | |
| 773 | 0 |
_tCancer _gvol. 123 _gno. 3 _gp. 449-458 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.30325 _zAvailable from publisher's website |
| 999 |
_c26473011 _d26473011 |
||